Figure EV5. GLK inhibitor attenuates ACE2 protein levels, ACE2‐containing exosomes, and SARS‐CoV‐2 pseudovirus infection.

• A–D
  Human ACE2 KI mice were intranasally infected with SARS‐CoV‐2 pseudovirus on Day 0 and Day 1. Mice were also treated with the GLK inhibitor verteporfin on Day 0 after infection. n = 3 (biological replicates) per group. Infection efficiencies of SARS‐CoV‐2 pseudovirus in mouse tissues were measured by IVIS and presented as luminescence counts on Day 2 (A). Immunoblotting of ACE2 and vinculin in the lung tissues of the infected hACE2 KI mice with/without the GLK inhibitor verteporfin (10 μM in 100 μl) treatment (B). Immunoblotting of ACE2 and CD9 in exosomes isolated from the sera (C) and BALF (D) of the infected mice with/without the GLK inhibitor verteporfin (10 μM in 100 μl) treatment. Arrowhead denotes glycosylated ACE2 proteins; asterisk denotes unglycosylated ACE2 proteins.

Data information: WT, wild‐type mice; KI, hACE2 knockin mice.